NasdaqCM - Delayed Quote USD

Alzamend Neuro, Inc. (ALZN)

0.7195 -0.0065 (-0.90%)
At close: April 26 at 4:00 PM EDT
0.7500 +0.03 (+4.24%)
After hours: April 26 at 6:29 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Stephan Jackman CEO & Director 434.24k -- 1977
Mr. David J. Katzoff Chief Financial Officer 116.67k -- 1963
Mr. Milton Charles Ault III Founder & Vice Chairman -- -- 1970
Mr. Henry C. W. Nisser Esq. Executive VP, General Counsel & Director 50k -- 1969
Mr. Kenneth S. Cragun CPA Senior Vice President of Finance -- -- 1961

Alzamend Neuro, Inc.

3480 Peachtree Road NE
Second Floor, Suite 103
Atlanta, GA 30326
United States
844 722 6333 https://www.alzamend.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
4

Description

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Corporate Governance

Alzamend Neuro, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Related Tickers

BCDA BioCardia, Inc.
0.3766
+2.95%
 
AZTR Azitra, Inc.
0.2185
-0.73%
 
ENSC Ensysce Biosciences, Inc.
0.5842
+1.69%
 
SMMT Summit Therapeutics Inc.
3.8600
+8.73%
 
FNCH Finch Therapeutics Group, Inc.
2.3200
+3.11%
 
ATHE Alterity Therapeutics Limited
2.5100
+9.61%
 
KA Kineta, Inc.
0.6100
-2.37%
 
LIPO Lipella Pharmaceuticals Inc.
0.7110
+0.98%
 
KZIA Kazia Therapeutics Limited
0.3700
+1.43%
 
FBRX Forte Biosciences, Inc.
0.7163
-0.07%